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Open access under CC BYRecent studies have compared rates of acute myocardial infarction before and after introducing smoking
bans. Some meta-analyses report post-ban reductions up to 19%, implausibly large considering likely
changes in smoking habits and passive smoke exposure. Our literature reassessment demonstrates major
weaknesses in many studies and meta-analyses, including failure to consider data from control areas or
existing trends in acute myocardial infarction rates, incorrect estimation of variability, and use in some
meta-analyses of results for population subsets or estimates apparently unrelated to the data reported.
We report meta-analyses using a consistent approach to derive estimates of the ban effect, taking account
of time trends and control data, which indicate a much smaller reduction. Preferring national to regional
estimates where available, we estimate a 5% reduction (95% CI 3–8%). Omitting estimates where trend
adjustment was impossible, this becomes 2.7% (2.1–3.4%), consistent with reported declines of 2–3% in
large national populations (England, France, Italy, USA). We discuss some limitations of these estimates.
Further evidence is needed, possibly by analyzing national mortality data. Our ﬁndings highlight the need
for a valid approach when estimating the effect of bans, and demonstrate major weaknesses in many pre-
vious publications.
 2011 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Various reviews have concluded that there is an increased risk
of heart disease in smokers (US Surgeon General, 2004; Yusuf
et al., 2004) that declines quite rapidly on quitting (US Surgeon
General, 1990) .There is also an increased risk in never smokers ex-
posed to ETS (Glantz and Parmley, 1991, 1995; He et al., 1999; Law
et al., 1997), though recent reviews (Enstrom and Kabat, 2006; Lee
et al., 2010) indicate that this association is quite weak, particu-
larly in the USA where meta-analyses based on 16 studies give a
relative risk (RR) of only 1.07 with a 95% conﬁdence interval (CI)
of 1.02–1.13 (Lee et al., 2010).
Evidence also exists that smoking bans lead to a reduction in
the prevalence of smoking and in consumption per smoker (Bauer
et al., 2005; Fichtenberg and Glantz, 2002; Gallus et al., 2006; He-
loma and Jaakkola, 2003; Lemstra et al., 2008) and to a marked
reduction in cotinine levels in nonsmokers (Haw and Gruer,
2007; Pechacek et al., 2007), consistent with substantially reducedute coronary syndrome; AMI,
ease; CI, conﬁdence interval;
te matter less than 2.5 lm
-NC-ND license.ETS exposure. Based on this one might expect some reduction in
AMI risk following a ban.
In the ﬁrst study of the effect of smoking bans on heart disease,
Sargent et al. (2004) reported a 40% reduction in hospital admis-
sions from acute myocardial infarction (AMI) in Helena, Montana,
USA subsequent to the introduction of a local law banning smoking
in public places and in workplaces. Over the following years, fur-
ther such studies have been carried out and Glantz (2008) pre-
sented the results of a meta-analysis of eight published studies,
concluding that smoking bans were associated with a reduction
in AMI rates by 19% (95% CI 14–24%). Various other reviews have
also been carried out (e.g. Lightwood and Glantz, 2009; Mackay
et al., 2010; Meyers et al., 2009) and the Committee on Secondhand
Smoke Exposure and Acute Coronary Events of the US Institute of
Medicine (2010) concluded that there was a causal relationship be-
tween smoking bans and a decreased risk of AMI, and felt that the
magnitude of risk reduction observed in the published studies of
smoking bans and heart disease is consistent with what might be
expected from comparison with changes in exposure to particulate
matter less than 2.5 lm across (PM2.5) following a ban.
Having noted that the estimates presented in the source publi-
cations for the individual studies, and also in the reviews, are based
on a variety of methods to assess the effect of a smoking ban, many
failing to use data from control populations, many ignoring the evi-
dent underlying downward trends in AMI admission rates in Eur-
ope, the US and Canada (Sims et al., 2010), some selectively
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and/or incorrectly calculating the variability of the estimated
reduction in risk, we decided to attempt to derive our own esti-
mate from each study using consistent and logical criteria. We also
decided to consider all relevant published studies so as to get an
updated overall meta-analysis estimate of the effect of a ban, and
to compare the overall estimates given in earlier reviews with
those calculated using our derived study estimates.
The main objectives of this paper are to highlight the need for a
valid and consistent approach when estimating the effect of a
smoking ban on disease risk, and to obtain more reliable estimates
of the effect using all the available data.2. Materials and methods
2.1. Literature searching
Published studies and reviews relating smoking bans to risk of
AMI (or heart disease) were sought from searches on PubMed
and Scopus using the terms described by Mackay et al. (2010),
and from papers cited in relevant publications.2.2. Objectives and general approach
For each study identiﬁed as providing relevant information on
smoking bans, estimates of the effect of the ban were derived from
the published data, and compared with those derived by the origi-
nal author and those used in recent reviews by Glantz (2008), the
Institute of Medicine (2010), Lightwood and Glantz (2009), Mackay
et al. (2010) and Meyers et al. (2009). Meta-analyses based on the
derived estimates were compared with those presented in these
reviews.
The studies of interest typically compare risk of AMI in a popu-
lation where a ban has been introduced, presenting numbers of
cases or rates for one or more periods before the ban, and for
one or more comparable periods after the ban. They may also pres-
ent corresponding data for a control population where such a ban
has not been introduced. In analyzing such data, it seems particu-
larly important to us to account for the tendency for the risk of AMI
to decrease over successive years (Sims et al., 2010), and to vary
seasonally within a year. While most studies take seasonal varia-
tion into account by presenting results only for comparable periods
(e.g. June to November in each year), many studies do not take the
annual trend into account. Taking account of the trend is important
to avoid confounding.
Given that a publication provides data from a control popula-
tion, it seems to us that using these data to estimate the effect of
the ban is the appropriate thing to do, as the underlying trends
in AMI rates and the factors that cause them are likely to be similar
in the ban and control populations, so that comparison of pre-ban
to post-ban changes in the two areas should automatically account
for time trends quite precisely.
Where data from such a control population are not available,
time trends should be taken into account. Where data are available
in the study for multiple similar time periods pre-ban, adjustment
for trend can be carried out using these data. Where data are avail-
able only for a single period pre-ban and post-ban, adjustment for
possible time trends has to be made based on information on the
magnitude of the time trend derived from other studies.
While the methods we describe for estimating the effects of a
ban use control data when available, and take time trends into ac-
count, some other general points concerning our methods of esti-
mation should be mentioned. As the time period of the studies is usually quite short, adjust-
ment for the linear effect of time trends should generally be
adequate. However, consideration should be given to factors
that might affect linearity. For example, if there are changes
in diagnostic criteria at a given time point, it would seem sensi-
ble to estimate the trend only from data for the years after the
change.
 As the great majority of studies consider the post-ban period as
starting immediately or just after the ban, we derive estimates
on this basis, where possible.
 We consider it generally adequate to derive estimates from
numbers of AMI cases, ignoring changes in population size. Over
a short term, such changes will generally be minor. Over a
longer term, they will be taken into account in the adjustment
for trend (as longer term studies typically report data for multi-
ple periods).
 Where a study provides data for multiple control populations,
we generally estimate the effect of the ban from the combined
control data. However, control populations with obvious weak-
nesses may be excluded.
 Some studies report results for subgroups by sex, age or smok-
ing habit. The estimates we use in our meta-analyses are always
based on the result for the whole study population, and not on
that for subsets.
 Where possible, we investigate, using standard methods (Lee,
1999), the possibility that RRs and 95% CIs reported in the
source papers or reviews may have statistical errors.
 Our mathematical methods assume that the effect of a ban is to
multiply the risk of AMI by a given factor, with the factor invari-
ant of the length of time post-ban. We investigate the effect of
this assumption by comparing the estimates of the magnitude
of the ban effect in studies with shorter and longer post-ban
periods.
2.3. Estimating the ban RR and the time trend
For studies with a control area (Scenario 1), the RR associated
with a ban is estimated by
RR1 ¼ ðNTA=NCAÞ=ðNCB=NTBÞ ð1aÞ
where N is the number of cases, subscripts T and C refer to the test
and control area, respectively, and subscripts B and A refer to the
period before the ban and after the ban, respectively. The variance
of the logarithm of RR1, V1 is estimated by
V1 ¼ ð1=NTAÞ þ ð1=NTBÞ þ ð1=NCAÞ þ ð1=NCBÞ ð1bÞ
with the lower and upper 95% CI of RR1 estimated by
RRL1; RRU1 ¼ expðlog RR1  Z
ﬃﬃﬃﬃﬃﬃ
V1
p
Þ ð1cÞ
where Z is the standard normal deviate corresponding to 0.025.
For studies with no control area, but for which data are avail-
able on the number of cases occurring in successive periods pre-
ban and in one or more periods post-ban (Scenario 2), Poisson
log-linear regression analysis (Draper and Smith, 1998), performed
using SAS Version 9.2 (SAS Institute Inc,, Cary, NC, USA), was used
to predict the number of cases post-ban, N^TA, and its variance, U.
Here RR2 and V2 are estimated by
RR2 ¼ NTA=N^TA; and ð2aÞ
V2 ¼ ð1=NTAÞ þ ð1=UÞ ð2bÞ
with the 95% CI estimated by
RRL2; RRU2 ¼ exp ðlog RR2  Z
ﬃﬃﬃﬃﬃﬃ
V2
p
Þ ð2cÞ
For studies with no control area and no trend information (Sce-
nario 3), RR3 and V3 are estimated by
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where M refers to the mean number of cases per year (or period of
interest), and
V3 ¼ ð1=NTAÞ þ ð1=NTBÞ ð3bÞ
with the 95% CI estimated by
RRL3;RRU3 ¼ exp ðlog RR3  Z
ﬃﬃﬃﬃﬃﬃ
V3
p
Þ ð3cÞ2.4. Meta-analyses
Independent RR estimates from multiple studies were then
combined using random-effects meta-analysis (Fleiss and Gross,
1991). Meta-analyses were based on the overall set of studies or
were based on the studies considered in the selected recent review
papers (Glantz, 2008; Institute of Medicine, 2010; Lightwood and
Glantz, 2009; Mackay et al., 2010; Meyers et al., 2009).3. Results
3.1. The studies
Twenty-four studies were identiﬁed, published between 2004
and 2011. In ﬁve the bans were in national populations – England
(Sims et al., 2010), France (Thomas et al., 2010), Italy (Barone-Adesi
et al., 2011), Scotland (Pell et al., 2008) and USA (Shetty et al.,
2011); four were in US states – Arizona (Herman and Walsh,
2011), Delaware (Moraros et al., 2010), Massachusetts (Dove
et al., 2010; Massachusetts Department of Public Health, 2008)
and New York State (Juster et al., 2007); ﬁve were in smaller areas
of the USA – Bowling Green, Ohio (Khuder et al., 2007), Helena,
Montana (Sargent et al., 2004), Jefferson County, Texas (McAlister
et al., 2010), Monroe County, Indiana (Seo and Torabi, 2007) and
Pueblo, Colorado (Alsever et al., 2009; Bartecchi et al., 2006); four
were in areas of Italy – Piedmont (Barone-Adesi et al., 2006), Rome
(Cesaroni et al., 2008), Tuscany (Gasparrini et al., 2009) and in four
areas (Vasselli et al., 2008); with the remaining six in various
places – Barcelona, Spain (Villalbí et al., 2009), Christchurch, New
Zealand (Barnett et al., 2009), Graubuenden, Switzerland (Trachsel
et al., 2010), Saskatoon, Canada (Lemstra et al., 2008), Southwest
Ireland (Cronin et al., 2007) and Toronto, Canada (Naiman et al.,
2010). In total, there were data from nine countries. Details of
the individual studies are discussed in Section 3.3.
3.2. The reviews
The ﬁrst review considered (Glantz, 2008) presented RRs and
95% CIs from eight studies (Barone-Adesi et al., 2006; Bartecchi
et al., 2006; Cesaroni et al., 2008; Cronin et al., 2007; Juster et al.,
2007; Khuder et al., 2007; Lemstra et al., 2008; Sargent et al.,
2004) citing an overall random-effects estimate of 0.81 (95% CI
0.76–0.86). This was an update of an earlier meta-analysis (Dinno
and Glantz, 2007).
The review by Lightwood and Glantz (2009) presented RRs and
95% CI’s from eleven studies, citing a similar overall estimate of
0.81 (0.78–0.85). This included data from three new studies (Mas-
sachusetts Department of Public Health, 2008; Pell et al., 2008;
Vasselli et al., 2008) and also included results from both the earlier
(Bartecchi et al., 2006) and later (Alsever et al., 2009) publications
from the study in Pueblo, Colorado.
The review by Meyers et al. (2009) reported RRs and 95% CIs
from 10 studies, with an overall estimate of 0.83 (0.75–0.92). Com-
pared with Lightwood and Glantz (2009), two studies published as
press releases or as abstracts were omitted (Cronin et al., 2007;Massachusetts Department of Public Health, 2008), while one addi-
tional study was included (Seo and Torabi, 2007).
The same 10 studies were considered in the report by the Insti-
tute of Medicine (2010). This report described the characteristics
and reported results of these studies in detail, but did not conduct
a meta-analysis, though it noted that the decreases following a ban
‘‘ranged from about 6% to 47%.’’
The ﬁnal review we considered, by Mackay et al. (2010), pro-
duced an overall estimate of 0.90 (0.86–0.94). This was based on
35 effect size estimates from 15 studies. This included all the stud-
ies noted in Section 3.1 with the exception of eight (Barone-Adesi
et al., 2011; Dove et al., 2010; Gasparrini et al., 2009; McAlister
et al., 2010; Moraros et al., 2010; Thomas et al., 2010; Trachsel
et al., 2010; Villalbí et al., 2009).
It should be noted that the detailed source of the estimates used
in meta-analyses is generally not presented in any of these re-
views, and that the estimates used for the same study in different
reviews often vary. While some of the estimates used are pre-
sented in the original study publications and some can be derived
quite simply using standard formulae, the source of a number of
estimates is quite unclear, as will become further apparent in Sec-
tion 3.3. Table 1 lists the 24 studies and shows which were consid-
ered in each of the reviews.
3.3. Study details and estimates
In the following subsections, we go though the studies in turn,
summarizing their main features, giving our derived RR (95% CI)
estimate and explaining, where relevant, how and why this differs
from that given in the reviews.
Study 1: Helena, Montana, USA (Sargent et al., 2004)
A ban was introduced in Helena on 5th June 2002 and rescinded
on 3rd December the same year. Sargent et al. (2004) reported AMI
admissions among adults 18+ years in June to November for 1998,
1999 . . .2003 separately for those living in the ban area (33, 37, 42,
50, 24 (ban) and 39) and for those living in a control area outside it
(9, 11, 12, 14, 18 (ban) and 16). Three of the reviews (Glantz, 2008;
Institute of Medicine, 2010; Lightwood and Glantz, 2009) gave an
estimated RR of 0.60 (95% CI 0.21–0.99), equivalent to the estimate
of 16 (0.3–31.7) given by the authors for the fall in admissions from
an average of 40 per year in the ﬁve periods with no ban to 24 in
the period of the ban. This is not a usual method of determining
the 95% CI of an RR, and Meyers et al. (2009) gave an estimate of
0.60 (0.39–0.92), using standard formulae (as in formulae 3). The
95% CI of the estimate of 0.60 (0.36–1.00) given by Mackay et al.
(2010) appears to be calculated as if the ﬁgure of 40 admissions re-
lated only to a single period. None of the above estimates take into
account the control data or the trend. Our own estimate of 0.38
(0.19–0.76) uses the control data (based on formulae 1) and
ignores the data for 2003, as no other study has data for a situation
where a ban is introduced and then rescinded. Had we included the
2003 data, however, our estimate would have changed slightly, to
0.41 (0.21–0.81).
Study 2: Piedmont, Italy (Barone-Adesi et al., 2006)
A ban was introduced on 10th January 2005 in Italy. Barone-
Adesi et al. (2006) reported numbers of AMI admissions and age-
standardized rates in Piedmont, Italy by year and age group (<60,
60+ years) for the period February to June for the years 2001–
2005, and also age-adjusted RRs comparing the post-ban period
(2005) and the immediate pre-ban period (2004). Three reviews
(Glantz, 2008; Institute of Medicine, 2010; Lightwood and Glantz,
2009) cited the age-adjusted RR of 0.89 (95% CI 0.81–0.98) for
men and women combined aged <60 years, ignoring the corre-
sponding RR of 1.05 (1.00–1.11) for age 60+ years. Meyers et al.
(2009) gave an estimate of 1.08 (1.05–1.12) which was unex-
plained, and not obviously derivable from the data provided in
Table 1
Studies considered in this and earlier reviews.
Study Location Reference Considered in reviews by
Glantza Lightwoodb Meyersc Mackayd
1 Helena, Montana, USA Sargent et al. (2004) U U U U
2 Piedmont, Italy Barone-Adesi et al. (2006) U U U U
3 Pueblo, Colorado, USA Bartecchi et al. (2006) U U U U
Alsever et al. (2009) U U U
4 Southwest Irelande Cronin et al. (2007) U U U
5 New York State, USA Juster et al. (2007) U U U U
6 Bowling Green, Ohio, USA Khuder et al. (2007) U U U U
7 Monroe County, Indiana, USA Seo and Torabi (2007) U U
8 Rome, Italy Cesaroni et al. (2008) U U U U
9 Saskatoon, Saskatchewan, Canada Lemstra et al. (2008) U U U U
10 Massachusetts, USAf Massachusetts Department of Public Health (2008) U
Dove et al. (2010)
11 Scotland Pell et al. (2008) U U U
12 Four areas, Italyg Vasselli et al. (2008) U U U
13 Christchurch, NZ Barnett et al. (2009) U
14 Tuscany, Italy Gasparrini et al. (2009)
15 USAh Shetty et al. (2009) Ui
Shetty et al. (2011)
16 Barcelona, Spain Villalbí et al. (2009)
17 Jefferson County, Texas, USA McAlister et al. (2010)
18 Delaware, USA Moraros et al. (2010)
19 Toronto, Ontario, Canada Naiman et al. (2010) U
20 England Sims et al. (2010) U
21 Francej Thomas et al. (2010)
22 Graubuenden, Switzerland Trachsel et al. (2010)
23 Italy Barone-Adesi et al. (2011)
24 Arizona, USAk Herman and Walsh (2011) U
a Glantz (2008).
b Lightwood and Glantz (2009).
c Meyers et al. (2009) – the same studies were considered by the Institute of Medicine (2010).
d Mackay et al. (2010).
e Published only as an abstract.
f The earlier reference is a press release.
g The four areas were Piedmont, Lazio, Friuli Venezia Giulia and Campania. Note that study 2 also gives results for Piedmont, while Rome (study 15) is in Lazio.
h The earlier reference is an internal report.
i The paper was considered by the review but its results were not used in meta-analysis.
j Published only as a poster.
k Although the ﬁnal publication appeared in 2011, essentially the same publication was available in 2010.
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unadjusted estimates by age and sex derived from the numbers
of cases presented for the 2004 and 2005 periods, estimates which
were very similar to the adjusted estimates in the source paper.
Neither the source paper, nor any of the reviews took into account
the earlier data. Our own estimate of 0.96 (0.91–1.02) is based on
the overall numbers of AMIs for 2002–2005, and takes trend into
account using formulae 2. Separate estimates by age and sex are
males <60: 0.87 (0.77–1.00), females <60: 0.74 (0.54–1.03), males
60+: 1.00 (0.91–1.09) and females 60+: 1.01 (0.90–1.12). We have
ignored the data for 2001 as new diagnostic criteria were imple-
mented about that time (Cesaroni et al., 2008) which could have
led to an artiﬁcial change in the AMI admission rate. It should be
noted that study 23, of Italy itself, restricted attention to data from
2002, apparently for this reason (Barone-Adesi et al., 2011).
Study 3: Pueblo, Colorado, USA (Alsever et al., 2009; Bartecchi
et al., 2006)
A ban was introduced in Pueblo on 1st July 2003. The authors
of the earlier paper (Bartecchi et al., 2006) compared AMI hospi-
talization rates in the 18 months before the ban (January 2002 to
June 2003) and in the 18 months after the ban (July 2003 to
December 2004) inside Pueblo city limits, and also in two control
areas where the ban did not apply, outside Pueblo city limits and
in El Paso County. Unadjusted and seasonally adjusted RRs com-
pared the post-ban and pre-ban periods in each of the three
areas. Two of the reviews (Glantz, 2008; Institute of Medicine,
2010) cited the unadjusted estimate of 0.73 (95% CI 0.63–0.85),based on a simple comparison of the 399 cases pre-ban and the
291 post-ban (formulae 3), ignoring the control data, while the
review by Lightwood and Glantz (2009) gave a similar ﬁgure of
0.73 (0.64–0.82). Our alternative estimate based only on the re-
sults in the ﬁrst paper (Bartecchi et al., 2006) of 0.75 (0.63–
0.90) uses the control data for El Paso County (984 cases pre-
ban, 955 post-ban) ignoring the data for outside Pueblo city limits
(89 cases pre-ban 76 post-ban), which may have been affected by
the ban. Using the combined control data gives a similar estimate
(0.76, 0.64–0.90).
The authors of the later paper (Alsever et al., 2009) presented
results for a further 18 month period post-ban (January 2005 to
June 2005), during which the number of cases seen were 237 inside
Pueblo city limits, 92 outside the limits and 1230 in El Paso. The
numbers of cases in El Paso were also revised from those given
in the ﬁrst paper (Bartecchi et al., 2006) to 1299 pre-ban and
1241 in the ﬁrst post-ban period. Mackay et al. (2010) cited an
unadjusted estimate of 0.59 (95% CI 0.51–0.70), based on a simple
comparison of the cases pre-ban and those in the second post-ban
period (formulae 3), again ignoring the control data. Meyers et al.
(2009) cited an estimate of 0.30 (0.25–0.35), which is unexplained,
and seemingly totally inconsistent with the data cited in the
source, both in terms of magnitude of effect, and narrowness of
the 95% CI. Our alternative estimate of 0.70 (0.60–0.81) uses the
whole of the post-ban period and incorporates the control data
from El Paso County. Including the combined control data gives
0.70 (0.60–0.80).
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The ban was introduced in Ireland on 29th March 2004. In an
abstract Cronin et al. (2007) reported 1277 admissions with acute
coronary syndrome (ACS) in the year ending 28th March 2004 and
1092 in the year starting 29th March 2004. Our estimate of 0.86
(95% CI 0.79–0.93) based on those numbers (formulae 3) is the
same as that given by Mackay et al. (2010). Two other reviews
(Glantz, 2008; Lightwood and Glantz, 2009) gave a slightly different
estimate of 0.89 (0.81–0.97), the basis for this not being explained.
Study 5: New York State, USA (Juster et al., 2007)
A ban was introduced in New York State on 24th July 2003. Jus-
ter et al. (2007) reported numbers of AMI admissions from 1995 to
2004 and, based on a time trend analysis involving the monthly
data, estimated that rates were reduced by 8% as a result of the
ban, equivalent to an RR of 0.92, but gave no 95% CI. Our own esti-
mate of 0.92 (95% CI 0.91–0.93) is based on a comparison (using
formulae 2) of the number of cases observed in 2004 with that ex-
pected from the existing trend in 1995–2002, ignoring the result
for 2003, partly before and partly after the ban. This is the same
as given by Mackay et al. (2010). Two reviews (Glantz, 2008; Light-
wood and Glantz, 2009) gave an estimate of 0.80 (0.80–0.80). The
source of this is unclear, as AMI rates only varied by 10% over the
whole study period. Also, even comparing periods based on the
very large numbers of cases studied, the 95% CI should not be
the same to two decimal places. Meyers et al. (2009) gave an esti-
mate of 0.98 (0.97–0.99). This can be derived, using formulae 3, by
a simple comparison of mean cases pre- and post-ban, ignoring the
trend.
Study 6: Bowling Green, Ohio, USA (Khuder et al., 2007)
A ban was introduced in Bowling Green in March 2002 and
Khuder et al. (2007) presented hospital admission rates for coro-
nary heart disease (CHD) among adults aged 18+ years for each
year from 1999 to 2004 and, multiplied by two, for the ﬁrst half
of 2005, separately for Bowling Green and for Kent, Ohio as an con-
trol area. Two reviews (Glantz, 2008; Lightwood and Glantz, 2009)
cited an RR of 0.61 (95% CI 0.55–0.67), equivalent to a statement in
the source paper that admission rates declined from 36 per 10,000
in 2002 to 22 per 10,000 in 2003, a 39% decrease (33–45%). This
estimate ignores the control data and, since the ban was in March
2002, compares inappropriate periods, 2002 not being a pre-ban
year at all, but a year that was mainly post-ban. Mackay et al.
(2010) also gives an RR of 0.61, but with 95% CI of 0.48–0.77, their
method of estimation being unclear. Meyers et al. (2009) gave an
estimate 0.81 (0.59–1.11) based on changes in average incidence
rates for 1999–2001 (pre-ban) and 2003–2005 (post-ban). None
of these estimates used the control data and none related to the
precise periods before and after the ban. As the source paper pre-
sented monthly data for admissions in both periods, our estimate
of 0.98 (0.77–1.26) is based on the number of cases in March
1999 to February 2002 (pre-ban) and in March 2002 to February
2005 (post-ban), in both Bowling Green and Kent, using formulae
1. Data for January and February 1999 and for March to June
2005 were not used, to avoid confounding by seasonal effects. It
was notable that in Bowling Green, numbers of cases were actually
higher in the year immediately after the ban than in any other
years, and that the analysis in the various reviews all either omit
the whole of 2002 or wrongly consider 2002 as a pre-ban period.
Study 7: Monroe County, Indiana, USA (Seo and Torabi, 2007)
A ban was introduced in Monroe County on 1st August 2003
and Seo and Torabi (2007) present data on AMI admissions for Au-
gust 2001 to May 2003 (pre-ban) and for August 2003 to May 2005
(post-ban), separately for Monroe County and for Delaware
County, Indiana where no ban had been introduced. Results were
given separately for smokers and nonsmokers. This study was
not considered in two reviews (Glantz, 2008; Lightwood and
Glantz, 2009), but the Institute of Medicine (2010) refers to a70% decrease and give a 95% CI of 2.81–21.19. While this citation
corresponds to what was given in the source paper, the results only
concerned cases in Monroe County in nonsmokers, and the 95% CI
relate to the absolute difference in rates, and not to the percentage
decrease, the correct RR for this comparison being 0.29 (95% CI
0.11–0.80). The two other reviews (Mackay et al., 2010; Meyers
et al., 2009) give an estimate of 0.48 (0.24–0.96) apparently based
on data for Monroe County for smokers and nonsmokers com-
bined, though we estimate the 95% CI as 0.27–0.86. Our estimate
of 0.57 (0.23–1.38) also considers data for smokers and nonsmok-
ers, but takes the control data, from Delaware County, into account.
Study 8: Rome, Italy (Cesaroni et al., 2008)
This was a further study resulting from the ban introduced in
Italy on 10th January 2005. Cesaroni et al. (2008) presented data
on numbers and rates of acute coronary events (ACE) among
men and women aged 35+ years for each year from 2000 to
2005. They compared rates in 2005 with those predicted from a
trend analysis for the years 2000–2004, giving RR estimates of
0.89 (95% CI 0.85–0.93), 0.92 (0.88–0.97) and 1.02 (0.98–1.07),
respectively, for ages 35–64, 65–74 and 75–84 years. They also
presented estimates for males and females separately for ages
35–64 and 65–74 years. While one review (Mackay et al., 2010)
included separate age- and sex-speciﬁc results in their meta-
analyses, two reviews (Glantz, 2008; Lightwood and Glantz, 2009)
cite only the estimate for age 35–64 years, one review (Institute of
Medicine, 2010) cites only those for ages 35–64 and 65–74 years,
while another review (Meyers et al., 2009) cites only that for age
75–84 years (though with slightly different 95% CI of 0.98–1.05).
All these estimates are open to question, as they failed to take into
account the changes in diagnostic criteria implemented during the
study period, as mentioned for study 2 in Piedmont (Barone-Adesi
et al., 2006). It is apparent from inspection of the rates by year (e.g.
for age 35–64 2.05, 1.98, 2.13, 1.95, 1.92 and 1.80 per 1000 for
years 2000–2005) that ﬁtting a trend to data for the years from
2002 would be more appropriate than including data for the years
before the changes. If one restricts attention to 2002–2005, as did
Barone-Adesi et al. (2011), one gets our estimate of 0.98 (0.93–
1.02) for all age groups combined. Note that the corresponding
estimate for age 35–64 is 1.00 (0.93–1.08), indicating that the sig-
niﬁcant reduction originally reported for this age group may well
have been an artefact of the diagnostic change.
Study 9: Saskatoon, Saskatchewan, Canada (Lemstra et al., 2008)
A ban was introduced in the city of Saskatoon on 1st July 2004.
Lemstra et al. (2008) presented data on hospital discharges for AMI
for the 12 month period after the ban (July 2004 to June 2005) and
for eight similar periods before it. Noting that there was a change
in coding in April 2000, they compared the rate in the period post-
ban with the average rate in the four previous periods, giving an
estimated ban effect of 0.87 (95% CI 0.84–0.90), an estimate which
was cited in three reviews (Glantz, 2008; Institute of Medicine,
2010; Lightwood and Glantz, 2009). However, the 95% CI had
clearly been miscalculated, being far too narrow for the given num-
bers of cases. Mackay et al. (2010) give an alternative estimate of
0.87 (0.75–1.02) apparently based on the same comparison, with
wider 95% CI. The estimate of 0.91 (0.80–1.02) given by Meyers
et al. (2009) is consistent with a similar comparison but based on
the numbers of AMIs in each period, rather than the rates. None
of these estimates consider the trend. Our own estimate of 0.90
(0.76–1.07) uses the data for the same ﬁve periods, but takes trend
into account.
Study 10: Massachusetts, USA (Dove et al., 2010; Massachusetts
Department of Public Health, 2008)
A ban was introduced in Massachusetts on 5th July 2004. Dove
et al. (2010) used data on AMI deaths among those aged 35+ years
from 1999 to 2006 to estimate the effect of the ban using a model
which took into account a linear trend in the death rate, as well as
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inﬂuenza rates and city- or town-speciﬁc demographic factors.
The adjusted RR was 0.93 (95% CI 0.87–0.97), an estimate we will
use in the absence of available data to develop our own standard
estimate. The ban effect was noted to be clearer in the areas where
there was no local smoking ban in effect (0.90, 0.86–0.95), than in
areas where there was a ban (1.01, 0.92–1.11). This publication
was not considered in the various reviews considered. However,
Lightwood and Glantz (2009) give an estimate of 0.82 (0.76–
0.89) based on a press release in 2008 (Massachusetts Department
of Public Health, 2008). As far as we can see, this release does not
given this estimate, or data fromwhich it can be calculated, though
it makes clear that the analysis had been adjusted for trend and for
the factors noted above.
Study 11: Scotland (Pell et al., 2008)
A ban was introduced in Scotland at the end of March 2006. Pell
et al. (2008) compared admissions from ACS in nine hospitals in
Scotland in the 10 month period starting two months after the
ban with the same period a year earlier. Based on the number of
cases pre-ban (3235) and post-ban (2684) they estimated a ban ef-
fect of 0.83 (95% CI 0.82–0.84), an estimate similar to that of 0.83
(0.82–0.86) used by Lightwood and Glantz (2009). Based on formu-
lae 3 our own estimate is 0.83 (0.79–0.87), identical to that given
by Meyers et al. (2009). That the 95% CI of the estimates given orig-
inally by Pell et al. (2008) were wrongly calculated is indicated by
the fact that the review by Mackay et al. (2010), which includes
Pell as an author, used age and sex speciﬁc estimates with much
broader 95% CI than those given originally, which are consistent
with formulae 3. None of these estimates take time trend into
account.
Study 12: Four areas, Italy (Vasselli et al., 2008)
In the third study based on the ban in Italy on 10th January
2005, Vasselli et al. (2008) reported AMI hospital admissions and
rates in men and women aged 40 to 64 years separately for the
years 2001–2005 and for Piedmont, Friuli Venezia Giulia, Latium
and Campania. In an analysis based on rates, taking the pre-ban
trend into account, they reported a ban effect of 0.86 (95%CI
0.83–0.92) for the four areas considered. They also presented sep-
arate estimates by area, by sex and by ﬁve year age group. This
estimate was used by Lightwood and Glantz (2009) and is errone-
ously presented as 0.6 (0.83–0.92) in the Institute of Medicine re-
port (2010). Meyers et al. (2009) cited an estimate of 1.09 (1.00–
1.19) for the combined results from Friuli Venezia Giulia and
Campania, excluding the other areas for which results were sepa-
rately reported (Barone-Adesi et al., 2006; Cesaroni et al., 2008),
although one of these studies was conducted in Rome and not in
the whole region of Latium. This analysis clearly does not take
the trend into account, as the estimates for Friuli Venezia Giulia
(0.92, 0.78–1.13) and Campania (0.89, 0.83–0.98) both indicate a
beneﬁt of the ban. It appears to be based on the total cases pre-
and post-ban in the two areas combined, ignoring trend. Mackay
et al. (2010) cite separate estimates for Friuli Venezia Giulia, Camp-
ania and Latium which differ from those given by Vasselli et al.
(2008), being calculated from a simple comparison of cases in
2005 and 2004, ignoring the trend. To avoid possible bias due to
diagnostic changes, and for consistency with the other studies in
Italy (see comments on studies 2 and 8) our estimates are based
only on the data from 2002 onwards and take trend into account,
using formulae 2. For the combined regions, our estimate is 0.88
(0.80–0.96) while excluding Piedmont it is 0.91 (0.82–1.01).
Study 13: Christchurch, New Zealand (Barnett et al., 2009)
A ban was introduced in New Zealand in December 2004. Bar-
nett et al. (2009) compared hospital admissions for AMI in men
and women aged 30+ years in 2003–2004 and in 2005–2006. In
calculations which take population variation into account, they
estimated a ban effect of 0.92 (95% CI 0.86–0.99) and also gave esti-mates jointly by age (30–54, 55–74, 75+ years) and sex. Mackay
et al. (2010) include age and sex speciﬁc estimates. These differ
from those given in the source paper, but can be reproduced using
formulae 3, based on the number of cases pre-ban and post-ban,
except for males aged 30–54 years where Mackay et al. (2010) give
1.04 (0.83–1.31) but we calculate 1.08 (0.86–1.35). For the overall
population, a similar calculation gives our estimate of 0.95 (0.88–
1.02). None of these calculations account for possible trend. Our
estimate of 1.05 (0.85–1.31) is based on the numbers of AMI cases
by year, taking trend into account using formulae 2.
Study 14: Tuscany, Italy (Gasparrini et al., 2009)
In a fourth study following the ban in Italy on 10th January
2005, Gasparrini et al. (2009) presented data on numbers and
age adjusted rates for AMI death or hospitalization in the Tuscany
population aged 30–64 years annually from 2000 to 2005. Compar-
ing the observed rate in 2005 with that predicted assuming a linear
trend over the preceding four years, they estimated the ban effect
as 0.95 (95% CI 0.89–1.00). However, they noted that a non-linear
model gave a signiﬁcantly (p = 0.01) improved ﬁt, their preferred
estimate, based on a non-linear trend being 1.01 (0.93–1.10). The
rates by year (1.20, 1.25. 1.29, 1.25, 1.23, 1.20 per 1000 for
2000–2005, respectively) show a pattern (a rise from 2000 to
2002 and then a fall) that is identical to that seen in study 8 in
Rome (Cesaroni et al., 2008). As for that study, and the other Italian
studies (Barone-Adesi et al., 2006, 2011; Vasselli et al., 2008), we
prefer to estimate the ban effect based on the trend from 2002 on-
wards. On that basis, using formulae 2, our estimate of 0.99 (0.92–
1.07) is similar to that given by Gasparrini et al. (2009) assuming a
non-linear trend.
Study 15: USA (Shetty et al., 2009, 2011)
In 2009, Shetty et al. (2009) published a report describing anal-
yses that they had conducted based on US regional data from 1990
to 2004 on the timing of smoking bans and on deaths and hospital
admissions from various diseases. Assuming a common underlying
time trend in all regions they presented estimates of the percent-
age change in AMI (with 95% CI) associated with a ban, separately
for deaths and hospital admissions, by type of ban (workplace or
any) and by age. Subsequently, the authors published (Shetty
et al., 2011) a paper which included somewhat revised estimates.
For mortality, based on 2018,548 AMI deaths, they presented esti-
mates of +1.9% (95% CI 0.9% to +4.7%) for the change following
workplace smoking restrictions and of +1.3% (1.1% to 3.6%) for
the change following any smoking restrictions. For hospital admis-
sions, based on 673,631 AMI cases, their corresponding estimates
were 2.0% (7.0% to +3.0%) following workplace smoking restric-
tions and of 1.8% (6.7% to +3.1%) following any smoking restric-
tions. Given that most of the other studies relate to admissions,
and most concern restrictions in public places, we will use this ﬁ-
nal estimate, converting it to an RR of 0.98 (0.93–1.03). It should be
noted that the 95% CI seems rather wide, given the large number of
admissions studied – much wider than for study 5, in New York
State, and somewhat wider than for study 10, in Massachusetts.
This appears to be partly because the analyses only concerned 4%
of all hospital admissions in the relevant period, and partly because
of the quite complex nature of their statistical methods. Mackay
et al. (2010), the only one of the reviewers to consider this study,
noted that ‘‘it could not be included in the meta-analyses, because
it did not provide the information necessary to calculate relative
risk and conﬁdence intervals.’’
Study 16: Barcelona, Spain (Villalbí et al., 2009)
The ban was introduced in Spain on 1st January 2006, and Vil-
lalbí et al. (2009) presented age and sex speciﬁc numbers and rates
of AMI discharges for 2004, 2005 and 2006 for those aged 25+
years. This study was not considered by any of the key reviews.
Our estimate of 0.95 (95% CI 0.89–1.02) is based on the total num-
ber of episodes for each year, and takes trend into account. The
324 P.N. Lee, J.S. Fry / Regulatory Toxicology and Pharmacology 61 (2011) 318–331authors noted that the decline from 2005 to 2006 exceeded that
from 2004 to 2005 but gave no estimate of the decline in risk asso-
ciated with the ban.
Study 17: Jefferson County, Texas, USA (McAlister et al., 2010)
In the autumn of 2000 and continuing for ﬁve years, intensive
anti-smoking activities were introduced in Jefferson County. McAl-
ister et al. (2010) compared changes in AMI mortality rates be-
tween 1996–2000 and 2001–2005 in Jefferson County and in
other Texas counties. They calculated the net changes in trends
as 1.93 (SE 0.727), implying a greater rate of decline in Jefferson
County. Data on numbers of AMI deaths per year are not presented,
but it is possible to estimate the RR (95%) as 0.84 (95% CI 0.77–
0.91), based on formulae 1 using the individual year rates pre-
sented graphically in the source paper, and population estimates.
Apart from the difﬁculty of making precise estimates from data
presented graphically, two other problems should be noted. First,
the results do not speciﬁcally relate to a ban introduced at a partic-
ular point in time, and are therefore not completely comparable
with the results from the other studies considered. Second, Jeffer-
son County was selected for intensive anti-smoking activity specif-
ically because its rate of tobacco-related diseases were higher than
in the rest of Texas (McAlister et al., 2010). As a result, the esti-
mates may be biased due to ‘‘regression towards the mean’’ (Bland
and Altman, 1994).
Study 18: Delaware, USA (Moraros et al., 2010)
A ban was introduced in Delaware in November 2002, and Mor-
aros et al. (2010) presented quarterly data from quarter 1 1999 to
quarter 4 2004, separately for residents of Delaware and for non-
Delaware residents, on AMI hospitalizations recorded on the state
hospital discharge database. Ignoring 2002 quarter 4, which in-
cluded the ban, there were 6769 cases pre-ban and 3441 post-
ban in Delaware residents, with 1300 cases pre-ban and 679
post-ban in non-Delaware residents. Using formulae 1, this gives
an RR of 0.97 (95% CI 0.88–1.08). This can be compared with esti-
mated RRs of 0.95 (0.91–0.99) in Delaware residents and 0.98
(0.90–1.08) in non-Delaware residents given by Moraros et al.
(2010). They also reported a greater reduction (RR = 0.91, 95% CI
0.87–0.95) in Delaware residents when adjustments were made
for the increasing population of Delaware over the study period,
but, in the absence of corresponding data on the number of visitors
to Delaware, our estimate cannot be adjusted for population size.
Study 19: Toronto, Ontario, Canada (Naiman et al., 2010)
Three phases of smoking bans were introduced in Toronto. The
ﬁrst, implemented in October 1999, related to all public places and
workplaces; the second, in June 2001, related to restaurants, dinner
theatres and bowling centers; and the third, in June 2004, related
to bars, billiard halls, bingo halls, casinos and race tracks. Naiman
et al. (2010) analyzed hospital admission rates for six conditions,
including AMI, from January 1996 to March 2006, using an autore-
gressive integrated moving-average model to isolate the effect of
the bans from existing time trends. Over the period, rates of AMI
fell from about 6.6 per 1000 aged 45+ to 4.8 per 1000 judging from
data presented graphically. The authors presented estimates of the
absolute change in rates, with 95% CI, associated with the succes-
sive bans: in public places, workplace etc. 0.171 (0.59 to 0.40);
in restaurants etc. 0.477 (0.95 to 0.003); and in bars 0.611
(1.03 to 0.19). These three estimates are equivalent, respec-
tively, to RRs of about 1.03, 0.92 and 0.90, based on the average
rate over the study period which we estimate as 6.15 per 1000.
The authors also present an estimate of a 17% decrease (14–19%)
for the decrease associated with phase 2, equivalent to an RR of
0.83 (0.81–0.86). Both the RR and its 95% CI seem inconsistent with
the results reported for the change in rates. Based on the change in
rates, the RR should be about 0.92, and the 95% CI should be indic-
ative of a marginally signiﬁcant relationship, the upper limit being
very close to 1, not the hugely signiﬁcant result cited. In view of themultiple phases of the bans, we do not consider it possible to de-
rive an estimate that can usefully be compared with estimates
for the other studies. Mackay et al. (2010) cite an estimate of
0.70 (0.69–0.72), but the source of this is not known. We note that
the narrowness of their CI conﬂict markedly with that given by
Naiman et al. (2010) for the changes following any of the bans,
and that the decline in rates over the whole 11 year period is less
than 30%.
Study 20: England (Sims et al., 2010)
A ban was introduced in England on 1st July 2007. Sims et al.
(2010) collected weekly data on AMI admissions from July 2002
to September 2008 among adults aged 18+ years, and carried out
analyses adjusting for time trends, seasonal variation, and popula-
tion size and also adjusted for other AMI predictors (temperature,
ﬂu rates and Christmas holidays). For the whole population the
percentage change resulting from the ban was estimated as
2.37 (95% CI 4.06 to 0.66), equivalent to an RR of 0.98
(0.96–0.99). Separate estimates were also given by age and sex,
equivalent to RRs of 0.97 (0.94–0.99) for males aged <60 years,
0.97 (0.95–0.99) for males aged 60+ years, 0.98 (0.92–1.03) for fe-
males aged <60 years, and 0.96 (0.94–0.99) for females aged 60+
years. The age- and sex-speciﬁc data given by Mackay et al.
(2010) are virtually the same as this. The authors present the
weekly data only in graphical form that we cannot really use for
our own calculations, the only numerical data on AMI admissions
being annual numbers for 2002–2007. These data cast some doubt
on the assumption of linearity of the trend in the years preceding
the ban, with the declining trend after 2004 signiﬁcantly
(p < 0.001) more marked than before. While it is not possible to
carry out our own estimates, due to the lack of data on numbers
of cases for any deﬁned post-ban period, we shall use the estimate
of 0.98 (0.96–0.99) from the source paper, though there is some
concern as to its validity.
Study 21: France (Thomas et al., 2010)
A ban was introduced in France on 15th November 2006. In a
poster, Thomas et al. (2010) graphically presented data on num-
bers of hospitalizations from ACS occurring each month from Jan-
uary 2003 to June 2009 recorded in a national database. They
reported no clear effect of the ban, consistent with visual impres-
sions from the graph, which show a steadily declining trend with
seasonal ﬂuctuations. Our estimate of 0.98 (95% CI 0.97–0.99) is
based on an analysis (using formulae 2) of cases occurring in suc-
cessive 11 month periods from December to October, starting with
December 2003 to October 2004 and ending with December 2007
to October 2008, thus avoiding possible seasonal effects and the
use of November, the month in which the ban occurred.
Study 22: Graubuenden, Switzerland (Trachsel et al., 2010)
A ban was introduced in the canton of Graubuenden on 1st
March 2008. Trachsel et al. (2010) compared the number of AMI
hospitalizations occurring in March 2008 to February 2009 with
those recorded in the two preceding years. Numbers were also gi-
ven by sex, age and smoking habits. They reported a 22% decline
post-ban, which was noted to be signiﬁcant at p < 0.05 compared
to each of the previous 12-month periods. Our RR estimate, taking
trend into account, is 0.72 (95% CI 0.52–0.98).
Study 23: Italy (Barone-Adesi et al., 2011)
The last study we consider resulting from the ban in Italy on
10th January 2005 was based on hospital admissions for ACE re-
corded in the National Hospital Discharge Database for 2002–
2006. In an analysis based on monthly data up to November
2006 (December 2006 being omitted to avoid loss of information
for patients admitted in December 2006 and discharged in 2007),
and adjusted for time trends and seasonal variation, Barone-Adesi
et al. (2011) estimated an RR of 0.98 (95% CI 0.97–1.00). A signiﬁ-
cant effect was noted for those aged under 70 years (0.96, 0.95–
0.98), but not in older men and women (1.00, 0.99–1.02). Effect
Table 2
Comparison of our estimates and meta-analyses with those given by Glantz (2008).
Study Location RR (95% CI) Formulaea
Estimate given Our estimate
1 Helena, Montana, USA 0.60 (0.21–0.99) 0.38 (0.19–0.76) 1
2 Piedmont, Italy 0.89 (0.81–0.98) 0.96 (0.91–1.02) 2
3 Pueblo, Colorado, USA 0.73 (0.63–0.85) 0.75 (0.63–0.90)b 1
4 Southwest Ireland 0.89 (0.81–0.97) 0.86 (0.79–0.93) 3
5 New York State, USA 0.80 (0.80–0.80) 0.92 (0.91–0.93) 2
6 Bowling Green, Ohio, USA 0.61 (0.55–0.67) 0.98 (0.77–1.26) 1
8 Rome, Italy 0.89 (0.85–0.93) 0.98 (0.93–1.02) 2
9 Saskatoon, Saskatchewan, Canada 0.87 (0.84–0.90) 0.90 (0.76–1.07) 2
Random-effects meta-analysis 0.81 (0.76–0.86) 0.92 (0.87–0.96)
a The formulae apply to our estimates. Formulae 1 use the data for the test and control areas, formulae 2 adjust for trend, in the absence of data for a control area, and
formulae 3 simply compare the pre-ban and post-ban period. See methods for full details.
b Based on the data reported by Bartecchi et al. (2006).
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estimate of 0.97 (0.96–0.98) based on numbers of cases in 2002–
2005, ignoring the incomplete data for 2006, and taking trend into
account.
Study 24: Arizona, USA (Herman and Walsh, 2011)
A ban was introduced in Arizona in May 2007. Herman and
Walsh (2011) presented data on AMI admissions in May 2007 to
April 2008 and in the three previous 12-month periods, separately
for those counties with county or municipal smoking bans
pre-existing before May 2007 and counties with no previous bans.
Corresponding data were also presented for various other smoking-
related and non smoking-related diseases. A signiﬁcant (p < 0.05)
decline in AMI following the ban was noted in the counties with
no previous bans but not in the counties with pre-existing bans.
There is some confusion regarding the ﬁgures presenting the re-
sults as to whether the numbers given are rates (per 100,000) as
suggested by the heading of the ﬁgures, or whether they are num-
bers of admissions as indicated by the labeling of the y-axis as
‘‘number of diagnoses’’. We believe that they are numbers of
admissions, and that the analyses took population size into ac-
count. On the basis that many of the previous bans considered in
other studies took place following earlier restrictions, our estimate
of 0.99 (95% CI 0.82–1.19) is based on the combined admissions for
the two groups of counties, and takes trend into account (as in for-Table 3
Comparison of our estimates and meta-analyses with those given by Lightwood and Glan
Study Location RR (
Estim
1 Helena, Montana, USA 0.60
2 Piedmont, Italy 0.89
3 Pueblo, Colorado, USA
Bartecchi et al. (2006) 0.73
Alsever et al. (2009) 0.59
Combined
4 Southwest Ireland 0.89
5 New York State, USA 0.80
6 Bowling Green, Ohio, USA 0.61
8 Rome, Italy 0.89
9 Saskatoon, Saskatchewan, Canada 0.87
10 Massachusetts, USA 0.82
11 Scotland 0.83
12 Four areas, Italy
All areas 0.86
Excluding Piedmont
Random-effects meta-analysis 0.81
a The formulae apply to our estimates. Formulae 1 use the data for the test and contr
formulae 3 simply compare the pre-ban and post-ban period. See methods for full deta
b converted from the trend-corrected estimate of change given in the source paper.mulae 2). For the counties with no previous bans, our estimate is
0.90 (0.67–1.22), while for the countries with pre-existing bans it
is 1.05 (0.83–1.32). Although the ﬁnal version of the source paper
was published in 2011, an essentially identical version was avail-
able earlier (Herman and Walsh, 2010) and, based on this, Mackay
et al. (2010) derived an estimate of 0.88 (0.81–0.95). We were un-
able to determine how this had been calculated.3.4. Meta-analyses
Tables 2–4 concern, respectively, the meta-analyses of Glantz
(2008), Lightwood and Glantz (2009) and Meyers et al. (2009).
Each table shows the individual study estimates used in these re-
views and our alternative estimates. It also shows the correspond-
ing random-effects meta-analysis estimates.
In Tables 2 and 3, our overall RR estimates of, respectively, 0.92
(95% CI 0.87–0.96) and 0.90 (0.86–0.94) indicate a substantially
smaller reduction associated with a ban than the original estimates
of 0.81 (0.76–0.86) and 0.81 (0.78–0.85). Though, as discussed in
Section 3.3, the source of the estimates used by Glantz (2008)
and by Lightwood and Glantz (2009) is not always clear, reasons
for the differences include their failure to use data for control areas
for studies 1, 3 and 4, use of results for selected subsets of the pop-
ulation for studies 2 and 8, and use of estimates with implausiblytz (2009).
95% CI) Formulaea
ate given Our estimate
(0.21–0.99) 0.38 (0.19–0.76) 1
(0.81–0.98) 0.96 (0.91–1.02) 2
(0.64–0.82)
(0.49–0.70)
0.70 (0.60–0.81) 1
(0.81–0.97) 0.86 (0.79–0.93) 3
(0.80–0.80) 0.92 (0.91–0.93) 2
(0.55–0.67) 0.98 (0.77–1.26) 1
(0.85–0.93) 0.98 (0.93–1.02) 2
(0.84–0.90) 0.90 (0.76–1.07) 2
(0.76–0.89) 0.93 (0.89–0.97) Otherb
(0.82–0.86) 0.83 (0.79–0.87) 3
(0.83–0.92) –
0.91 (0.82–1.01) 2
(0.78–0.85) 0.90 (0.86–0.94)
ol areas, formulae 2 adjust for trend, in the absence of data for a control area, and
ils.
Table 4
Comparison of our estimates and meta-analyses with those given by Meyers et al. (2009).
Study Location RR (95% CI) Formulaea
Estimate given Our estimate
1 Helena, Montana, USA 0.60 (0.39–0.92) 0.38 (0.19–0.76) 1
2 Piedmont, Italy 1.08 (1.05–1.12) 0.96 (0.91–1.02) 2
3 Pueblo, Colorado, USAb 0.30 (0.25–0.35) 0.70 (0.60–0.81) 1
5 New York State, USA 0.98 (0.97–0.99) 0.92 (0.91–0.93) 2
6 Bowling Green, Ohio, USA 0.81 (0.59–1.11) 0.98 (0.77–1.26) 1
7 Monroe County, Indiana, USA 0.48 (0.24–0.96) 0.57 (0.23–1.38) 1
8 Rome, Italy 1.02 (0.98–1.05) 0.98 (0.93–1.02) 2
9 Saskatoon, Saskatchewan, Canada 0.91 (0.80–1.02) 0.90 (0.76–1.07) 2
11 Scotland 0.83 (0.79–0.87) 0.83 (0.79–0.87) 3
12 Four areas, Italy
Excluding Piedmont and Lazio 1.09 (1.00–1.19) –
Excluding Piedmont 0.91 (0.82–1.01) 2
Random-effects meta-analysis 0.83 (0.75–0.92) 0.89 (0.85–0.94)
a The formulae apply to our estimates. Formulae 1 use the data for the test and control areas, formulae 2 adjust for trend, in the absence of data for a control area, and
formulae 3 simply compare the pre-ban and post-ban period. See methods for full details.
b Based on the data reported by Alsever et al. (2009).
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the large study 5 makes a particularly great contribution to the dif-
ference in meta-analysis results.
In Table 4, the difference between our overall estimate of 0.89
(0.85–0.94) and the estimate of 0.83 (0.75–0.92) of Meyers et al.
(2009) is less marked, but still indicates a smaller reduction asso-
ciated with a ban. Major contributors to the difference appear to
derive from Meyers et al.’s use in study 3 of an extremely low RR
estimate with a quite narrow 95% CI for no obvious reason, and
the use of an estimate for the large study 5 which does not account
for trend.
Table 5 gives the estimates we have derived for each study (ex-
cept study 19 for reasons discussed in Section 3.3), together with
their inverse-variance weight, and the formulae used to calculate
them. It can be seen that, with the exception of studies 4 and 11,
all of our estimates take trend into account, either by use of data
from a control area or by comparison of post-ban incidence with
that expected from extrapolation of the observed log-linear trend
pre-ban.
It is notable that the study weights vary enormously, from over
10,000 for the national studies in England, France, Italy and for the
study in New York State, (though not for the national US study
which only covered 4% of hospital admissions) to under 100 for
studies 1, 6, 7, 13 and 22 conducted in small areas.
Table 5 also shows which studies were included in the review
by Mackay et al. (2010). Their individual estimates are given by
sex and age and are not directly comparable to ours. For the studies
they consider, which also includes study 19, which we did not,
their overall estimate is 0.90 (0.86–0.94), while our estimate is
quite similar at 0.91 (0.88–0.95). Our estimate is shown in Table 6,
along with some other estimates based on data now available.
More recent studies include national estimates for Italy and the
USA, countries where a number of regional estimates have also
been published. To avoid double-counting, we excluded regional
estimates where national estimates were available, giving an over-
all estimate from 10 studies (national studies in England, France,
Italy, Scotland and the USA, and regional studies in Canada, Ireland,
New Zealand, Spain and Switzerland) of 0.95 (0.92–0.97). Given
there were some concerns about study 15 in the USA, resulting
from the low weight of its estimate and the fact that coverage of
AMI admissions was very far from complete, we also present the
results of an alternative meta-analysis in which we omit the esti-
mate for study 15, but instead include estimates from the nine re-
gional US studies, giving a combined estimate of 0.92 (0.90–0.95).
We also repeated the last two meta-analyses, omitting studies 4
and 11 where there were no available data to adjust for trend.These gave combined estimates of 0.973 (0.966–0.979) including
study 15 and 0.94 (0.92–0.96) excluding study 15, again excluding
regional data where national data were available. It is interesting
to note that the estimate including study 15 was from the only
meta-analysis where there was not marked (p 6 0.001) heteroge-
neity of the estimates, reﬂecting the fact that the national esti-
mates from England, France, Italy and the USA were all very
similar, at 0.97 or 0.98.
Table 6 also compares RR estimates by study weight, by length
of follow-up period and by region. There was a consistent tendency
for the estimated effect of a ban to increase with decreasing
weight, but this was not statistically signiﬁcant (pP 0.05). There
was no indication that the effect of a ban varied by the length of
the follow-up period studied. The analyses for Europe give a com-
bined estimate of 0.94 (0.92–0.97). No signiﬁcant reduction (0.98,
0.93–1.02) was seen for North America when the results from
the national US study 15 were preferred to the regional US esti-
mates However preferring the regional data, the estimate became
signiﬁcant (0.89, 0.85–0.94). Also shown in Table 6 are some addi-
tional meta-analyses omitting study 17 as it was unusual in involv-
ing ongoing intensive anti-smoking activities, rather than a ban at
one speciﬁc time point. This had little effect on the estimates.4. Discussion
We carried out the work described in this paper because preli-
minary examination of some of the literature considered strongly
indicated that there were limitations in some of the primary and
meta-analyses conducted. Our ﬁndings strongly support this initial
view, and suggest that reviews (Glantz, 2008; Institute of Medi-
cine, 2010; Lightwood and Glantz, 2009; Mackay et al., 2010;
Meyers et al., 2009) have overestimated the reduction in risk fol-
lowing a smoking ban. The ﬁndings also emphazise the need for
a consistent approach, as far as possible, in deriving individual
study estimates, and the need for reviews to make the source of
all their estimates clear.
Although we were not always able to divine where all the esti-
mates used by reviewers came from, it was clear that a number of
important errors have been made. In the ﬁrst place, there were six
studies (1, 3, 6, 7, 17 and 18) where data were available from a
suitable control area without a ban, which the reviewers ignored
when estimating the effects of a ban. Dividing the decline in the
ban area by the ban in the control area can control for the effect
of common factors leading to changes in the AMI rate. Allowance
for trend was possible in all but two studies (4 and 11), where
Table 5
Our estimates.
Study Location Other details RR (95% CI) Weight Mackaya Formulaeb
1 Helena, Montana, USA 0.38 (0.19–0.76) 8 Yes 1
2 Piedmont, Italy 0.96 (0.91–1.02) 1071 Yes 2
3 Pueblo, Colorado, USA (a) Bartecchi et al. (2006) 0.75 (0.63–0.90) 125 – 1
(b) Alsever et al. (2009) 0.70 (0.60–0.81) 179 Yes 1
4 Southwest Ireland 0.86 (0.79–0.93) 589 Yes 3
5 New York State, USA 0.92 (0.91–0.93) 25,214 Yes 2
6 Bowling Green, Ohio, USA 0.98 (0.77–1.26) 63 Yes 1
7 Monroe County, Indiana, USA 0.57 (0.23–1.38) 5 Yes 1
8 Rome, Italy 0.98 (0.93–1.02) 2069 Yes 2
9 Saskatoon, Saskatchewan, Canada 0.90 (0.76–1.07) 132 Yes 2
10 Massachusetts, USA 0.93 (0.89–0.97) 2008 No Otherc
11 Scotland 0.83 (0.79–0.87) 1467 Yes 3
12 Four areas, Italy (a) All four areas 0.88 (0.80–0.96) 459 – 2
(b) Excluding Piedmont 0.91 (0.82–1.01) 347 Yes 2
13 Christchurch, NZ 1.05 (0.85–1.31) 82 Yes 2
14 Tuscany, Italy 0.99 (0.92–1.07) 672 No 2
15 USA 0.98 (0.93–1.03) 1540 No Otherc
16 Barcelona, Spain 0.95 (0.89–1.02) 744 No 2
17 Jefferson County, Texas, USA 0.84 (0.77–0.91) 569 No 1
18 Delaware, USA 0.97 (0.88–1.08) 373 No 1
20 England 0.98 (0.96–0.99) 12,670 Yes Otherc
21 France 0.98 (0.97–0.99) 26,326 No 2
22 Graubuenden, Switzerland 0.72 (0.52–0.98) 38 No 2
23 Italy 0.97 (0.96–0.98) 57,399 No 2
24 Arizona, USA 0.99 (0.82–1.19) 113 Yes 2
a Whether or not study considered by Mackay et al. (2010).
b Formulae 1 use the data for the test and control areas, formulae 2 adjust for trend, in the absence of data for a control area, and formulae 3 simply compare the pre-ban
and post-ban period. See methods for full details.
c Based on model-ﬁtting analyses by the original authors which took trend into account.
Table 6
Random-effects meta-analyses.
No. Description Estimates includeda Nb RR (95% CI)
As given in published reviews
1 Glantz (2008) See Table 2 8 0.81 (0.76–0.86)
2 Lightwood and Glantz (2009) See Table 3 12 0.81 (0.78–0.85)
3 Meyers et al. (2009) See Table 4 10 0.83 (0.75–0.92)
4 Mackay et al. (2010) See source paper 35 0.90 (0.86–0.94)
As calculated from our estimates
5 Glantz studies 1, 2, 3a, 4–6, 8, 9 8 0.92 (0.87–0.96)
6 Lightwood and Glantz studies 1, 2, 3b, 4–6, 8–11, 12b 11 0.90 (0.86–0.94)
7 Meyers et al. studies 1, 2, 3b, 5–9, 11, 12b 10 0.89 (0.85–0.94)
8 Mackay et al. studies 1, 2, 3b, 4–9, 11, 12b, 13, 20, 24 14 0.91 (0.88–0.95)
9 Excluding regional estimates where national estimates available 4, 9, 11, 13, 15, 16, 20–23 10 0.95 (0.92–0.97)
10 As 9, but ignoring US study 15 1, 3b, 4–7, 9–11, 13, 16–24 18 0.92 (0.90–0.95)
11 As 9, but omitting estimates where trend adjustment was not possible 9, 13, 15, 16, 20–23 8 0.973 (0.966–0.979)
12 As 10, but omitting estimates where trend adjustment was not possible 1, 3b, 5–7, 9, 10, 13, 16–24 16 0.94 (0.92–0.96)
Meta-analyses by study weight
13 Weight >10,000 5, 20, 21, 23 4 0.96 (0.94–0.99)
Weight 1001–10,000 2, 8, 10, 11, 15 5 0.93 (0.88–0.99)
Weight 501–1000 4, 14, 16, 17 4 0.91 (0.84–0.98)
Weight 101–500 3b, 9, 12b, 18, 24 5 0.89 (0.79–1.00)
Weight <100 1, 6, 7, 13, 22 5 0.80 (0.61–1.06)
Meta-analyses by length of post-ban periodc
14 15 months or less 1, 2, 4, 5, 8, 9, 11, 12b, 14, 16, 20,22–24 14 0.94 (0.91–0.96)
22 months or longer 3b, 6, 7, 10, 13, 18, 21 7 0.93 (0.86–0.99)
Meta-analyses omitting study 17 as no speciﬁc ban
15 As 10 1, 3b, 4–7, 9–11, 13, 16, 18–24 17 0.93 (0.90–0.95)
16 As 12 1, 3b, 5–7, 9, 10, 13, 16, 18–24 15 0.95 (0.92–0.97)
17 As 13, weight 501–1000 4, 14, 16 3 0.93 (0.86–1.01)
a See Table 5 for our estimates by number.
b Number of estimates.
c Omitting study 15 as length of follow-up varied by area, and study 17 as no speciﬁc ban.
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and no control area, but was inadequate in many others. Apart
from the six studies ignoring control data, there were four studies
(2, 9, 13 and 22) where adjustment for trend was not considered at
all, one study (12) where results of an adjusted analysis were ig-nored by reviewers, and the three studies in Italy (8, 12 and 14),
where the trend analyses conducted ignored changes in diagnostic
criteria, taken into account by the exclusion of results before 2002
in study 23, of all Italy. Other errors came from the use of estimates
with erroneous 95% CI in four studies (5, 9, 11 and 19), errors
Table 7
Estimating the decline in risk following a smoking ban given its effects on smoking
habits and on ETS exposure.
Group Smoking ETS Pre-ban Post-ban
Prevalence Risk Prevalence Risk
1 Never No PN(1  PE) 1 PN(1  FPE) 1
2 Never Yes PNPE RE PNFPE RE
1 + 2 Never All PN RN PN R0N
3 Current All PC RNRC PC  Q RNR0C
4 Short-term ex All PX RNRX PX + Q RNRX
5 Long-term ex No PY(1  PE) RY PY(1  FPE) RY
6 Long-term ex Yes PYPE RYRE PYFPE RYRE
5 + 6 Long-term ex All PY RYRN PY RYR
0
N
Note: RN = 1 + PE(RE  1), R0N = 1 + FPE(RE  1), and R0C = 1+(RC  1)V2/V1.
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et al., 2010; Meyers et al., 2009), and also from the use of selected
results for subsets of the population in three studies (2, 7 and 8) in
some of the meta-analyses. There are even some cases where
meta-analysts have used study-speciﬁc estimates that seem to
bear little relationship to the results reported. Particularly notable
are the estimated 70% decline in study 3 used by Meyers et al.
(2009), the estimated 20% decline in study 5 used in two reviews
(Glantz, 2008; Lightwood and Glantz, 2009), and the estimated
30% decline in study 19 used by Mackay et al. (2010), all of which
seem inexplicably large, and have an implausibly narrow 95% CI,
given the data. Another error was in study 6, where twometa-anal-
yses (Glantz, 2008; Lightwood and Glantz, 2009) based estimates
on comparison of data for 2002 and 2003, when the ban was in
March 2002.
While our meta-analyses are based on a consistent approach, a
number of difﬁculties nevertheless remain. Our approach adjusts
for trend on the assumption that the underlying trend is log-linear,
possibly somewhat inaccurate for longer studies. Also, we do not
take into account population changes, relying on the fact that these
are likely to be minor over the study period. There is also the prob-
lem that meta-analyses may not be fully comparing like with like.
We note that while the majority of studies considered AMI, a num-
ber considered ACS, ACE or CHD, some included secondary as well
as primary diagnoses, some were based on discharge diagnosis and
some on admission diagnosis, and some were restricted to fatal
events. It is possible that effects of a smoking ban may vary some-
what according to the diagnostic criteria used.
Another problem related to changes in diagnostic criteria for
AMI. Barone-Adesi et al. (2011) noted the changes introduced by
the European Society of Cardiology and the American College of
Cardiology in 2000 which may have induced an apparent increase
in the rate of hospital admissions thereafter. They restricted atten-
tion to admissions from 2002 onwards, and in our calculations we
decided also to restrict attention to that period when we estimated
the ban effect in the four studies (2, 8, 14 and 16) conducted in var-
ious areas of Italy, especially as the pre-ban data showed a smooth-
er trend if data before 2002 were ignored. Though changes in
diagnostic criteria at this time would not have affected the esti-
mates for studies with control areas or studies where the data con-
sidered started in 2002 or later, it should be noted that there were
four North American studies (Juster et al., 2007; Lemstra et al.,
2008; Dove et al., 2010; Shetty et al., 2011) where the pre-ban per-
iod extended from before 2002 to afterwards. We did not restrict
attention to the data for 2002 onwards for these studies, partly
as this was not possible from the data presented for two of them
(Dove et al., 2010; Shetty et al., 2011), and partly as no adjustment
for possible effects of diagnostic changes was made by the authors
of any of these papers. Restricting attention to data from 2002 on-
wards would have changed our estimate for study 5 (Juster et al.,
2007) from 0.92 (0.91–0.93) to 0.95 (0.94–0.96) and for study 9
(Lemstra et al., 2008) from 0.90 (0.76–1.07) to 0.97 (0.75–1.26),
suggesting that failure to fully adjust for changes in diagnostic cri-
teria might have led to some overestimation of the ban effect.
Also important are variations in the nature of the ban and in
whether more limited restrictions were available before the ban.
We excluded study 19 from our meta-analyses because there were
three phases of the ban, and it seemed difﬁcult or impossible to de-
rive an estimate that could usefully be compared with estimates
for the other studies. We did provide an estimate for study 17,
which concerned ﬁve years of anti-smoking advice, rather than a
ban at a single time point, but excluding it had little effect on
our meta-analyses.
Publication bias, a perennial potential problem in meta-analy-
ses, is perhaps more important than issues relating to variations
in diagnostic criteria or the nature of the ban. Our analysis showinga strong relationship of the estimated ban effect with study size,
with the smallest studies generating the largest effects, suggesting
either that some small studies ﬁnding no effect of a ban might
never have been published or, perhaps more likely, that bans tend
to be introduced, or studies conducted, in areas with unusually
high AMI rates, perhaps partly due to chance variation, with a
resultant bias due to ‘‘regression to the mean’’ (Bland and Altman,
1994). This possibility is particularly relevant for study 17, where
the study area, Jefferson County, was deliberately chosen as it
had the highest AMI rate in Texas.
While our paper makes the case for a consistent approach in
estimating the effect of a smoking ban, and makes it clear that
there were a large number of errors in the published reviews and
meta-analyses, it also provides our own estimates of the reduction
in risk of AMI associated with a smoking ban. All our estimates,
which vary in the range of 3–8% according to the studies included
(see Table 6), are smaller than those in any of the meta-analyses
we have considered (Glantz, 2008; Lightwood and Glantz, 2009;
Mackay et al., 2010; Meyers et al., 2009) which vary from 10% to
19%, and 11 of the 25 individual study estimates we derived (see
Table 5) indicate a smaller reduction than the range of 6–47%
noted by the Institute of Medicine (2010). While this is partly
due to these reviews not having available all the studies we consid-
ered – including the national studies in England, France and Italy
(Barone-Adesi et al., 2011; Sims et al., 2010; Thomas et al., 2010)
which only indicate a 2% or 3% decline – there are some studies
(2, 6 and 8) considered by all these reviews, where our estimate
of the ban effect is modest.
Given the evidence of an increased risk of heart disease in
smokers (US Surgeon General, 2004; Yusuf et al., 2004) that de-
clines quite rapidly on quitting (US Surgeon General, 1990), of an
increased risk in nonsmokers exposed to ETS (Glantz and Parmley,
1991, 1995; He et al., 1999; Law et al., 1997; Lee et al., 2010), and
given the evidence that smoking bans lead to a reduction in the
prevalence of smoking and in consumption per smoker (Bauer
et al., 2005; Fichtenberg and Glantz, 2002; Gallus et al., 2006; He-
loma and Jaakkola, 2003; Lemstra et al., 2008) and to a marked
reduction in cotinine levels in nonsmokers (Haw and Gruer,
2007; Pechacek et al., 2007), consistent with substantially reduced
ETS exposure, one might certainly expect there to be some reduc-
tion in AMI risk following a ban. However, it is questionable that
one would have expected anything like the almost 20% drop in
AMI rates following a ban estimated in some of the meta-analyses
(Glantz, 2008; Lightwood and Glantz, 2009; Meyers et al., 2009) or
the larger drops for studies 1, 3, 6 and 7 estimated in some of these
meta-analyses (see Tables 2–4). As shown in the Appendix, where
we estimate the expected magnitude of the reduction in heart dis-
ease rates following a smoking ban, none of our alternative
assumptions concerning the magnitude of the relevant relation-
ships generates a drop as large as this. Our estimates generally vary
Table 8
Estimated percentage decline in risk of heart disease following a ban based on the main parameter values and various alternatives.
Estimated percentage decline
Whole population Never smoked Ever smoked
1 Main parameter values 7.21 3.13 7.89
2 Vary assumed effect on ETS exposure from F = 0.6
2a F = 0.8 (20% reduction) 6.59 1.57 7.43
2b F = 0.4 (60% reduction) 7.83 4.70 8.36
2c F = 0.2 (80% reduction) 8.45 6.27 8.82
3 Vary assumed effect on smoking prevalence from Q = 0.038
3a Q = 0.02 (2% less current smokers) 6.49 3.13 7.06
3b Q = 0.06 (6% less current smokers) 8.08 3.13 8.91
4 Vary assumed effect on consumption per smoker from V2 = 16.9
4a V2 = 18 (2 less cigs/day) 5.87 3.13 6.33
4b V2 = 15 (5 less cigs/day) 9.53 3.13 10.60
5 Vary assumed RR for ETS exposure from RE = 1.18
5a RE = 1.10 6.72 1.90 7.53
5b RE = 1.30 8.03 5.22 8.51
6 Vary assumed smoking RRs from RC = 3, RX = 2, RY = 1.25
6a RC = 2, RX = 1.5, RY = 1.1 5.28 3.13 5.76
6b RC = 4, RX = 2.5, RY = 1.4 8.45 3.13 9.17
7 Vary assumed current and never smoking prevalence from PN = 0.25, PC = 0.25
7a PN = 0.40, PC = 0.10 5.81 3.13 6.84
7b PN = 0.10, PC = 0.40 8.20 3.13 8.46
8 Vary proportion of ex-smokers from PN = 0.25, PC = 0.25, PX = 0.15, PY = 0.35
8a PN = 0.35, PC = 0.35, PX = 0.1, PY = 0.2 8.30 3.13 9.50
8b PN = 0.15, PC = 0.15, PX = 0.2, PY = 0.5 5.97 3.13 6.26
Vary prevalence of ETS exposure in never and long-term ex-smokers from PE = 0.5
PE = 0.75 7.76 4.52 8.30
PE = 0.25 6.61 1.63 7.45
9 Extreme alternatives
9a F = 0.2, Q = 0.06, V2 = 15, RE = 1.3, RC = 4, RX = 2.5, RY = 1.4 14.64 10.43 15.21
9b F = 0.8, Q = 0.02, V2 = 18, RE = 1.1, RC = 2, RX = 1.5, RY = 1.1 2.87 0.95 3.30
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assumption that smoking prevalence and consumption per smoker
will reduce following the ban, the estimated drop in AMI admis-
sions in never smokers being always markedly less than that in
ever smokers.
More evidence is certainly needed to clarify the issue. It seems
to us that it would be useful to analyze data which are readily
available on heart disease death rates. In the USA, data are avail-
able at a state level on annual trends in rates and on whether,
and when, smoking bans were introduced. Similar national data
are also available for Western European countries. Model ﬁtting
to estimate the magnitude of the reduction following a ban should
be practical, and using data for the whole of these two large areas
should avoid dangers of publication bias and allow better charac-
terization of trends existing pre- and post-ban.
5. Conclusions
Our literature reassessment has demonstrated that there are
important weaknesses in many published studies and meta-analy-
ses. The most common include failure to take data from control
areas into account or to consider existing trends in AMI rates.
Other weaknesses include incorrect estimation of variability and
the use in some meta-analyses of results for population subsets
or of estimates that are apparently unrelated to the data reported.
While some previous meta-analyses have claimed that bans reduce
AMI rates by up to 19%, our more valid and consistent approach to
the derivation of estimates of the effect for each study, which as far
as possible takes account of time trends and control data, indicates
a much smaller reduction. Preferring national to regional estimates
where available, we estimate a 5% reduction (95% CI 3–8%). Omit-
ting estimates where we could not adjust for trend, the reduction
becomes 2.7% (2.1–3.4%), consistent with declines of 2–3% that
have been reported in large national populations (England, France,Italy and the US). Some difﬁculties remain in the interpretation of
these declines as a direct effect of the bans, and further evidence,
perhaps from detailed analysis of trends in heart disease mortality
in the US and Western Europe, might clarify the issue further. Our
ﬁndings highlight the need for a valid approach when estimating
the effect of bans, and demonstrate major weaknesses in much
previously published evidence.
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Appendix A
Estimating. the expected magnitude of the reduction in heart disease
rates following a smoking ban
Consider the population pre-ban as consisting of four groups –
never smokers, current smokers, short-term ex-smokers and
long-term ex-smokers – with prevalences of, respectively, PN, PC,
PX and PY. Effects of ETS exposure in current smokers and
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dominated by their smoking. The proportion of never smokers and
of long-term ex-smokers exposed to ETS is assumed to be PE.
Assume that a ban reduces the prevalence of current smokers
from PC to PC  Q with the prevalence of short-term ex-smokers
increasing from PX to PX + Q, that cigarette consumption in current
smokers reduces from V1 to V2, and that the proportion of never
smokers and long-term ex-smokers exposed to ETS reduces from
PE to FPE.
Deﬁne the following heart disease RRs compared to never
smokers: RC for current smokers of V1 cigs/day, RX for short-term
ex-smokers of V1 cigs/day, and RY for long-term ex-smokers of V1
cigs/day. Also deﬁne RE for the RR related to ETS exposure, and
RN for the RR for all never smokers relative to never smokers unex-
posed to ETS (the ‘‘unexposed’’ group).
Table 7 shows the pre- and post-ban distribution of the popu-
lation in groups subdivided by smoking and ETS exposure,
together with the risk relative to the unexposed. The overall risks
of the population pre-ban (RPRE) and post-ban (RPOST) relative to
the unexposed can then be estimated by summing the product
of prevalence and risk for groups 1–6, with Z = RPOST/RPRE the
ban effect, and 100(1  Z) the percentage decline in risk. The per-
centage decline in never smokers and in ever smokers can also be
similarly calculated based on the risks for groups 1–2, and 3–6,
respectively.
Points to note about the calculations and assumptions are:
(1) RC is revised downwards post-ban to R
0
C = (RC  1)V2/V1
to account for the reduced consumption of continuing
smokers,
(2) RN is revised downwards post-ban from RN = 1 + PE(RE  1)
pre-ban to R0N = 1 + FPE(RE  1) post-ban to account for the
reduced proportion of never smokers exposed to ETS.
(3) Pre-ban, the risk of a current smoker is given by RNRC. As this
risk is assumed unaffected by ETS exposure, the risk pre-ban
is estimated as RNR
0
C and not R
0
NR
0
C. Similarly the risk for a
short-term ex-smoker, relative to an unexposed individual,
remains at RNRX post-ban.
(4) It is assumed that, among never smokers and long-term ex-
smokers, the effect of the ban is to reduce the proportion
exposed to ETS and not the level of ETS exposure. If excess
risk is linearly related to the level of exposure, F can be inter-
preted equally well as a reduction in the proportion exposed
or in the level of exposure.
(5) No account has been taken of short-term ex-smokers
becoming long-term ex-smokers, as this would happen
regardless of the ban.
The parameter estimates used are given below:
Increased risks of heart disease in current smokers RC = 3, short-
term ex-smokers RX = 2, and long-term ex-smokers RY = 1.25
Based broadly on ﬁndings from large case–control studies (Bo-
setti et al., 1999; Negri et al., 1994; Rosenberg et al., 1985, 1990;
Teo et al., 2006), from the large CPS-II prospective study (US Sur-
geon General, 1989) and from statements made by the US Surgeon
General, 1990 concerning the decline in excess risk following
quitting.
Increased risk from ETS exposure RE = 1.17
Based on a recent meta-analysis of the available literature of the
risk of heart disease in never smokers associated with having a
spouse who currently smokes (Lee et al., 2010).
Effect of ban on prevalence of smoking Q = 0.038
Based on a review by Fichtenberg and Glantz (2002).
Daily cigarette consumption per smoker pre-ban V1 = 20
This varies by country but is typical of many countries (Forey
et al., 2006–2011).Reduction in consumption per smoker post-ban V2  V1 = 3.1
This is also based on the review by Fichtenberg and Glantz
(2002).
Effect of ban on ETS exposure F = 0.6
Equivalent to a 40% reduction for all nonsmokers consistent
with studies of cotinine level in New York (Pechacek et al., 2007)
and Scotland (Haw and Gruer, 2007).
Prevalences of smoking and of ETS exposure in never and long-term
ex-smokers PN = 0.25, PC = 0.25, PX = 0.15, PY = 0.35, PE = 0.50
These will depend on the population studied.
Table 8 shows the estimated decline in risk of heart disease
following a ban using the main parameter values, as described
above, and using various alternatives. For the main parameter
values the decline is estimated as 7.21%, with RPRE = 1.895 (equiv-
alent to 47% of deaths being attributable to smoking) and
RPOST = 1.749 (43% attributable). The decline in risk in never
smokers is estimated as 3.13% and in ever smokers as 7.89%.
Varying any of the parameters individually (see analyses 2–9 in
Table 8) gives estimates of the decline varying from only 5.28%
to 9.53%, with the decline always less in never smokers than in
those who have ever smoked. In analysis 10, using extreme alter-
natives for each of the seven parameters F, Q, V2, RE, RC, RX and RY,
the estimates vary from 2.87% to 14.64%.References
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